Petco: Some Signs Of A Turnaround, But Far From Changing My Mind (Q2 Review)

Petco Health reported flat Q2 revenue of $1.49B, with operational improvement attributed largely to one-off tariff refunds rather than underlying business momentum. The company carries $1.46B of long-term debt and only 1.5x interest coverage, underscoring balance-sheet risk. While management reaffirmed FY26 guidance including tariff-refund benefits, Q3 adjusted EBITDA guidance of $100M-$103M was below Q2, weighing on sentiment.

Analysis

The investable issue is not the quarter’s headline but earnings quality: non-recurring cash recoveries can support reported EBITDA while leaving store-level traffic, merchandise gross margin, and veterinary utilization unresolved. That weakens the probability that WOOF can delever organically, so equity upside remains capped by refinancing risk and creditors retain disproportionate influence over capital allocation. A sub-2x interest-coverage profile also makes even modest rate widening or an EBITDA miss material to equity value.

CHEWY is the clearest relative beneficiary if WOOF responds through promotion or reduced inventory investment: Chewy can absorb price competition through its autoship base and structurally lower fulfillment costs, while WOOF must protect cash. WMT and TGT are secondary beneficiaries in consumables, where pet food and litter are traffic-driving categories and their broader baskets permit more aggressive pricing. The more important second-order risk is vendor tightening: slower payment terms, lower cooperative advertising, or reduced inventory availability would impair WOOF’s in-stock position before it appears in reported revenue.

Near term, the stock may trade on guidance maintenance, but the 1-3 month catalyst path is negative if Q3 results show that EBITDA declines after the refund benefit rolls off or management cannot demonstrate positive comparable-sales and gross-margin momentum. Over 6-18 months, the key question is whether free cash flow can reduce leverage before refinancing becomes a central narrative; absent this, a strategic transaction or liability-management exercise becomes more plausible than multiple expansion. The bearish thesis is falsified by two consecutive quarters of positive core comps, durable margin expansion excluding recoveries, and demonstrable debt reduction from internally generated cash.

Key Decisions for Investors

• Maintain a short bias in WOOF only on rallies following guidance defense; use a 3-6 month horizon and size modestly given potential short-covering on any refinancing announcement. Cover if management delivers positive core comparable sales plus EBITDA above guidance without material one-off items.
• Express the competitive view as long CHEWY / short WOOF in equal-dollar terms over the next 1-3 months. The pair limits broad pet-category exposure while targeting WOOF’s financing and fixed-cost disadvantage; reassess if CHEWY signals incremental promotional pressure or WOOF reports improving traffic and veterinary productivity.
• Avoid treating tariff-related cash receipts as recurring valuation support. Set an alert for covenant amendments, debt exchange language, incremental asset-based borrowing, or vendor-payment commentary; any of these would be a signal to increase downside hedges rather than wait for a reported earnings miss.
• For investors unable to short, avoid WOOF equity and prefer CHEWY as the cleaner pet-sector exposure into the next earnings cycle. The relative upside is driven by share capture and less balance-sheet optionality risk, while the main risk is a broad discretionary-spending slowdown that weakens both names.